Skip to main content

Rituximab‐induced interstitial lung disease in a patient with immune thrombocytopenia purpura

Buy Article:

$43.00 plus tax (Refund Policy)


We report the case of an 84‐year‐old man with refractory immune thrombocytopenia purpura (ITP) who was treated with rituximab and subsequently developed severe interstitial lung disease. There has been increasing use of rituximab in the treatment of ITP with success rates of up to 62% in adult patients with recurrent ITP. Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Haematology, Auckland Hospital 2: Greenlane Respiratory Services, Auckland City Hospital, Auckland, New Zealand

Publication date: 2012-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more